All patients
Age < 65y (younger) Age > 65y Asian type ECOG 0 ECOG 1 PD-L1 < 1% PD-L1 > 1%
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
breast cancer (BC), pembrolizumab based treatment vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-119 (all population), 2019 0.97 [0.82; 1.15]
KEYNOTE-119 (PDL1 CPS>1), 2019 0.86 [0.69; 1.07]
KEYNOTE-119 (PDL1 CPS>10), 2019 0.78 [0.57; 1.06]
KEYNOTE-355 (all population), 2020 0.89 [0.76; 1.05]
KEYNOTE-355 (CPS>1), 2020 0.86 [0.72; 1.03]
KEYNOTE-355 (CPS>10), 2020 0.73 [0.56; 0.96]
0.87 [0.80 ; 0.95 ] KEYNOTE-119 (all population), 2019, KEYNOTE-119 (PDL1 CPS>1), 2019, KEYNOTE-119 (PDL1 CPS>10), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-355 (CPS>1), 2020, KEYNOTE-355 (CPS>10), 2020 6 0% 3,027 low serious progression or deaths (PFS)detailed results KEYNOTE-119 (all population), 2019 1.60 [1.33; 1.92]
KEYNOTE-119 (PDL1 CPS>1), 2019 1.35 [1.08; 1.68]
KEYNOTE-119 (PDL1 CPS>10), 2019 1.14 [0.82; 1.59]
KEYNOTE-355 (all population), 2020 0.82 [0.69; 0.97]
KEYNOTE-355 (CPS>1), 2020 0.75 [0.62; 0.91]
KEYNOTE-355 (CPS>10), 2020 0.66 [0.50; 0.88]
1.00 [0.75 ; 1.34 ] KEYNOTE-119 (all population), 2019, KEYNOTE-119 (PDL1 CPS>1), 2019, KEYNOTE-119 (PDL1 CPS>10), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-355 (CPS>1), 2020, KEYNOTE-355 (CPS>10), 2020 6 91% 3,027 low not evaluable DCRdetailed results KEYNOTE-119 (all population), 2019 0.60 [0.39; 0.94]
0.60 [0.39 ; 0.94 ] KEYNOTE-119 (all population), 2019 1 0% 622 NA not evaluable events or deaths (EFS)detailed results KEYNOTE-522, 2020 0.63 [0.43; 0.93]
0.63 [0.43 ; 0.93 ] KEYNOTE-522, 2020 1 0% 1,174 NA not evaluable objective responses (ORR)detailed results KEYNOTE-119 (all population), 2019 0.89 [0.53; 1.50]
KEYNOTE-119 (PDL1 CPS>1), 2019 1.35 [0.72; 2.54]
KEYNOTE-119 (PDL1 CPS>10), 2019 2.13 [0.90; 5.04]
KEYNOTE-355 (all population), 2020 0.24 [0.17; 0.33]
KEYNOTE-355 (CPS>1), 2020 1.28 [0.92; 1.80]
KEYNOTE-355 (CPS>10), 2020 1.62 [1.01; 2.60]
1.01 [0.47 ; 2.17 ] KEYNOTE-119 (all population), 2019, KEYNOTE-119 (PDL1 CPS>1), 2019, KEYNOTE-119 (PDL1 CPS>10), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-355 (CPS>1), 2020, KEYNOTE-355 (CPS>10), 2020 6 94% 3,027 low not evaluable pCR detailed results KEYNOTE-522, 2020 13.60 [6.77; 27.33]
13.60 [6.77 ; 27.33 ] KEYNOTE-522, 2020 1 0% 602 NA not evaluable AE (any grade)detailed results KEYNOTE-355 (all population), 2020 1.25 [0.41; 3.87]
KEYNOTE-522, 2020 0.25 [0.01; 4.74]
1.02 [0.35 ; 2.95 ] KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 2 1% 2,013 low not evaluable AE (grade 3-4)detailed results KEYNOTE-355 (all population), 2020 1.26 [0.91; 1.76]
KEYNOTE-522, 2020 1.35 [1.01; 1.80]
1.31 [1.05 ; 1.63 ] KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 2 0% 2,013 low not evaluable SAE (any grade)detailed results KEYNOTE-119 (all population), 2019 0.99 [0.66; 1.48]
0.99 [0.66 ; 1.48 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable TRAE (any grade)detailed results KEYNOTE-355 (all population), 2020 1.35 [0.68; 2.70]
KEYNOTE-522, 2020 0.25 [0.03; 2.00]
0.78 [0.17 ; 3.68 ] KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 2 56% 2,013 low not evaluable TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.29 [0.19; 0.43]
KEYNOTE-355 (all population), 2020 1.06 [0.78; 1.44]
KEYNOTE-522, 2020 1.26 [0.96; 1.66]
0.74 [0.33 ; 1.66 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 3 95% 2,614 low not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.37; 2.41]
KEYNOTE-355 (all population), 2020 2.00 [0.09; 44.58]
KEYNOTE-522, 2020 1.50 [0.16; 14.43]
1.06 [0.46 ; 2.44 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 3 0% 2,614 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results KEYNOTE-119 (all population), 2019 1.05 [0.42; 2.63]
KEYNOTE-522, 2020 2.16 [1.53; 3.05]
1.72 [0.89 ; 3.31 ] KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 2 52% 1,771 low not evaluable Abdominal pain TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18]
0.94 [0.06 ; 15.18 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11]
0.47 [0.02 ; 14.11 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64]
KEYNOTE-522, 2020 10.08 [0.59; 173.00]
5.06 [0.57 ; 44.81 ] KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 2 0% 1,771 low not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78]
KEYNOTE-355 (all population), 2020 0.83 [0.20; 3.51]
KEYNOTE-522, 2020 0.87 [0.36; 2.09]
0.86 [0.41 ; 1.80 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 3 0% 2,614 low not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.28 [0.08; 1.01]
KEYNOTE-355 (all population), 2020 1.15 [0.77; 1.71]
KEYNOTE-522, 2020 1.27 [0.91; 1.77]
1.03 [0.65 ; 1.65 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 3 60% 2,614 low not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.26 [0.28; 5.69]
KEYNOTE-522, 2020 1.40 [0.65; 3.02]
1.37 [0.69 ; 2.72 ] KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 2 0% 1,771 low not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11]
KEYNOTE-355 (all population), 2020 2.00 [0.09; 44.58]
KEYNOTE-522, 2020 3.51 [0.43; 28.62]
2.01 [0.43 ; 9.46 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 3 0% 2,614 low not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11]
KEYNOTE-522, 2020 0.50 [0.01; 25.13]
0.48 [0.04 ; 6.30 ] KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 2 0% 1,771 moderate not evaluable Cough TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64]
1.89 [0.06 ; 56.64 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11]
KEYNOTE-522, 2020 3.51 [0.43; 28.62]
2.02 [0.34 ; 12.03 ] KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 2 0% 1,771 low not evaluable Diabetes TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18]
KEYNOTE-522, 2020 1.99 [0.09; 44.34]
1.32 [0.17 ; 10.43 ] KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 2 0% 1,771 moderate not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.23 [0.05; 1.10]
KEYNOTE-522, 2020 1.71 [0.63; 4.67]
0.69 [0.10 ; 4.85 ] KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 2 78% 1,771 low not evaluable Dysgeusia TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 0.50 [0.01; 25.13]
0.50 [0.01 ; 25.13 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64]
1.89 [0.06 ; 56.64 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.19; 4.72]
KEYNOTE-355 (all population), 2020 1.15 [0.47; 2.82]
KEYNOTE-522, 2020 2.29 [0.94; 5.58]
1.51 [0.84 ; 2.72 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 3 0% 2,614 low not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.05 [0.00; 0.79]
KEYNOTE-522, 2020 1.13 [0.82; 1.57]
0.31 [0.01 ; 6.85 ] KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 2 79% 1,771 low not evaluable Headache TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64]
1.89 [0.06 ; 56.64 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 9.06 [0.52; 156.66]
9.06 [0.52 ; 156.66 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78]
KEYNOTE-355 (all population), 2020 1.00 [0.03; 29.90]
KEYNOTE-522, 2020 1.99 [0.09; 44.34]
1.31 [0.18 ; 9.44 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 3 0% 2,614 low not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 8.04 [0.46; 140.38]
8.04 [0.46 ; 140.38 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64]
KEYNOTE-355 (all population), 2020 2.00 [0.09; 44.58]
KEYNOTE-522, 2020 3.00 [0.15; 59.96]
2.29 [0.37 ; 14.11 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 3 0% 2,614 low not evaluable Increase AST TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.91 [0.57; 6.42]
KEYNOTE-522, 2020 9.67 [1.29; 72.54]
3.49 [0.75 ; 16.21 ] KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 2 45% 1,771 moderate not evaluable Increased ALT TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.90 [0.17; 21.02]
KEYNOTE-355 (all population), 2020 1.29 [0.67; 2.48]
KEYNOTE-522, 2020 2.34 [1.13; 4.86]
1.69 [1.05 ; 2.73 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 3 0% 2,614 low not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 2.53 [0.86; 7.45]
2.53 [0.86 ; 7.45 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.09 [0.01; 1.71]
KEYNOTE-355 (all population), 2020 0.83 [0.58; 1.19]
KEYNOTE-522, 2020 0.76 [0.57; 1.03]
0.78 [0.61 ; 1.00 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 3 8% 2,614 low not evaluable Maculopapular rash TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64]
1.89 [0.06 ; 56.64 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Myalgia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11]
0.47 [0.02 ; 14.11 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Myocarditis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.99 [0.09; 44.34]
1.99 [0.09 ; 44.34 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 5.72 [0.29; 114.60]
KEYNOTE-522, 2020 0.50 [0.01; 25.13]
2.32 [0.21 ; 25.15 ] KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 2 0% 1,771 moderate not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11]
KEYNOTE-355 (all population), 2020 1.13 [0.34; 3.69]
KEYNOTE-522, 2020 2.64 [1.01; 6.94]
1.77 [0.85 ; 3.67 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 3 0% 2,614 low not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78]
KEYNOTE-522, 2020 7.03 [0.40; 124.15]
3.49 [0.34 ; 35.41 ] KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 2 0% 1,771 low not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.01 [0.00; 0.12]
KEYNOTE-355 (all population), 2020 0.99 [0.73; 1.36]
KEYNOTE-522, 2020 1.06 [0.82; 1.38]
0.81 [0.42 ; 1.55 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 3 83% 2,614 low not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.13 [0.02; 1.08]
0.13 [0.02 ; 1.08 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 4.00 [0.21; 75.85]
4.00 [0.21 ; 75.85 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Pancytopenia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.24 [0.01; 5.23]
0.24 [0.01 ; 5.23 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.88 [0.62; 5.72]
1.88 [0.62 ; 5.72 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.16 [0.01; 3.13]
KEYNOTE-522, 2020 1.20 [0.42; 3.43]
0.72 [0.13 ; 4.06 ] KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 2 37% 1,771 low not evaluable Pneumonia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.24 [0.01; 5.23]
0.24 [0.01 ; 5.23 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 5.72 [0.29; 114.60]
KEYNOTE-355 (all population), 2020 6.05 [0.34; 108.78]
KEYNOTE-522, 2020 1.50 [0.16; 14.43]
3.15 [0.68 ; 14.57 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 3 0% 2,614 low not evaluable Pruritus TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64]
1.89 [0.06 ; 56.64 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18]
KEYNOTE-522, 2020 4.02 [0.50; 32.22]
2.39 [0.45 ; 12.62 ] KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 2 0% 1,771 low not evaluable Rash TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 3.51 [0.43; 28.62]
3.51 [0.43 ; 28.62 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Sarcoidosis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 0.50 [0.01; 25.13]
0.50 [0.01 ; 25.13 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Sepsis TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78]
0.94 [0.02 ; 47.78 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.90 [0.17; 21.02]
KEYNOTE-355 (all population), 2020 10.16 [0.59; 174.64]
KEYNOTE-522, 2020 15.50 [2.11; 114.09]
7.26 [1.88 ; 28.05 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 3 0% 2,614 low not evaluable Stomatitis TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11]
KEYNOTE-522, 2020 11.10 [0.65; 189.37]
2.64 [0.12 ; 57.65 ] KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 2 49% 1,771 low not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18]
0.94 [0.06 ; 15.18 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78]
KEYNOTE-522, 2020 1.99 [0.09; 44.34]
1.50 [0.13 ; 17.05 ] KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 2 0% 1,771 low not evaluable Urticaria TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64]
1.89 [0.06 ; 56.64 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Uveitis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 0.50 [0.01; 25.13]
0.50 [0.01 ; 25.13 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.51 [0.59; 3.82]
1.51 [0.59 ; 3.82 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Weight decreased TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.47 [0.04; 5.22]
0.47 [0.04 ; 5.22 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-30 07:39 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 64,370,336,147,145,355,337,146,317,4,319,144,356,351,357,352,354,353,358,359,324,142,305,306,98,96,269,60,143,270,140,240,3
- treatments: 847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561